Prevalence of obesity with type 2 diabetes highest in White children and lowest in Asian children
FRIDAY, Dec. 16, 2022 (HealthDay News) — Not all pediatric patients with type 2 diabetes have obesity, according to a systematic review and meta-analysis published online Dec. 15 in JAMA Network Open.
Milena Cioana, from McMaster University in Hamilton, Ontario, Canada, and colleagues conducted a systematic literature review to examine the prevalence of obesity in pediatric patients with type 2 diabetes.
Based on data from 53 articles (8,942 participants) included in the meta-analysis, the researchers found that the overall prevalence of obesity among pediatric patients with type 2 diabetes was 75.27 percent, while the prevalence of obesity at diabetes diagnosis was 77.24 percent. Male participants had higher odds of obesity than female participants (odds ratio, 2.10). Compared with other racial groups, Asian participants had the lowest prevalence of obesity (64.50 percent) and White participants had the highest prevalence of obesity (89.86 percent).
“Understanding the causes of type 2 diabetes in children without obesity is crucial to define the etiology of their diabetes and to create effective management strategies for this cohort,” the authors write. “Further research is needed to evaluate the causes of sex- and race and ethnicity-based associations of diabetes with obesity and explore additional factors that may affect the risk of developing type 2 diabetes apart from obesity in children.”
Weight-Loss Surgery Produces Lasting Diabetes Remission
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Study IDs Real-World Reasons for Lemborexant Discontinuation
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers